Saudi Pharmaceutical Industries and Medical Appliances Corporation

SASE:2070 Stock Report

Market Cap: ر.س4.6b

Saudi Pharmaceutical Industries and Medical Appliances Valuation

Is 2070 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2070 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2070 (SAR38.1) is trading below our estimate of fair value (SAR38.65)

Significantly Below Fair Value: 2070 is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2070?

Other financial metrics that can be useful for relative valuation.

2070 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.3x
Enterprise Value/EBITDA50.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 2070's PS Ratio compare to its peers?

The above table shows the PS ratio for 2070 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.5x
4016 Middle East Pharmaceutical Industries
10.4x13.0%ر.س3.3b
4015 Jamjoom Pharmaceuticals Factory
8.7x12.6%ر.س9.5b
002332 Zhejiang Xianju PharmaceuticalLtd
2.2x15.3%CN¥9.0b
600267 Zhejiang Hisun Pharmaceutical
0.8x5.6%CN¥9.0b
2070 Saudi Pharmaceutical Industries and Medical Appliances
2.7x9.4%ر.س4.6b

Price-To-Sales vs Peers: 2070 is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (5.5x).


Price to Earnings Ratio vs Industry

How does 2070's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 2070 is expensive based on its Price-To-Sales Ratio (2.7x) compared to the Asian Pharmaceuticals industry average (2.4x).


Price to Sales Ratio vs Fair Ratio

What is 2070's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2070 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.7x
Fair PS Ratio3.9x

Price-To-Sales vs Fair Ratio: 2070 is good value based on its Price-To-Sales Ratio (2.7x) compared to the estimated Fair Price-To-Sales Ratio (3.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2070 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentر.س38.10
ر.س34.88
-8.4%
16.6%ر.س45.00ر.س27.50n/a5
Mar ’25ر.س38.15
ر.س34.88
-8.6%
16.6%ر.س45.00ر.س27.50n/a5
Feb ’25ر.س34.15
ر.س34.88
+2.1%
16.6%ر.س45.00ر.س27.50n/a5
Jan ’25ر.س38.05
ر.س34.88
-8.3%
16.6%ر.س45.00ر.س27.50n/a5
Dec ’24ر.س36.05
ر.س34.88
-3.2%
16.6%ر.س45.00ر.س27.50n/a5
Nov ’24ر.س29.95
ر.س36.28
+21.1%
15.9%ر.س45.00ر.س27.50n/a5
Oct ’24ر.س35.00
ر.س42.83
+22.4%
21.4%ر.س55.50ر.س34.00n/a3
Sep ’24ر.س37.60
ر.س42.83
+13.9%
21.4%ر.س55.50ر.س34.00n/a3
Aug ’24ر.س39.70
ر.س37.83
-4.7%
34.7%ر.س55.50ر.س24.00n/a3
Jul ’24n/a
ر.س26.00
0%
7.7%ر.س28.00ر.س24.00n/a2
Jun ’24ر.س38.75
ر.س26.00
-32.9%
7.7%ر.س28.00ر.س24.00n/a2
May ’24ر.س25.20
ر.س26.00
+3.2%
7.7%ر.س28.00ر.س24.00n/a2
Apr ’24ر.س23.74
ر.س26.00
+9.5%
7.7%ر.س28.00ر.س24.00n/a2
Mar ’24ر.س22.06
ر.س26.00
+17.9%
7.7%ر.س28.00ر.س24.00ر.س38.152
Feb ’24ر.س23.02
ر.س27.00
+17.3%
3.7%ر.س28.00ر.س26.00ر.س34.152
Jan ’24ر.س21.90
ر.س27.00
+23.3%
3.7%ر.س28.00ر.س26.00ر.س38.052
Nov ’23ر.س25.80
ر.س31.00
+20.2%
9.7%ر.س34.00ر.س28.00ر.س29.952
Oct ’23ر.س26.15
ر.س31.00
+18.5%
9.7%ر.س34.00ر.س28.00ر.س35.002
Sep ’23ر.س27.75
ر.س31.00
+11.7%
9.7%ر.س34.00ر.س28.00ر.س37.602
Aug ’23ر.س28.95
ر.س34.50
+19.2%
18.8%ر.س41.00ر.س28.00ر.س39.702
Jul ’23ر.س26.00
ر.س34.50
+32.7%
18.8%ر.س41.00ر.س28.00n/a2
Jun ’23ر.س34.80
ر.س38.25
+9.9%
7.2%ر.س41.00ر.س35.50ر.س38.752
May ’23ر.س36.00
ر.س36.25
+0.7%
2.1%ر.س37.00ر.س35.50ر.س25.202
Apr ’23ر.س37.30
ر.س36.25
-2.8%
2.1%ر.س37.00ر.س35.50ر.س23.742
Mar ’23ر.س38.95
ر.س36.25
-6.9%
2.1%ر.س37.00ر.س35.50ر.س22.062

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.